cfDNA as a predictive marker for the prognosis of severe courses in patients with influenza-like symptoms with and without SARS-CoV-2 infections in General Practice: A prospective cohort study.
- Conditions
- J06.9U07.1Acute upper respiratory infection, unspecifiedCOVID-19, virus identified
- Registration Number
- DRKS00024722
- Lead Sponsor
- Institut für Allgemeinmedizin, Universitätsklinikum Essen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
Presence of symptoms of a flu infection.
Consent for blood draw, oropharyngeal or naso-pharyngeal swab for a rapid SARS-CoV-2 antigen test, subsequent PCR if necessary, and completion of a questionnaire.
Exclusion Criteria
Severe acute or chronic disease with known elevated cfDNA levels based on disease (including tumor disease, severe renal insufficiency, severe/moderate inflammation based on preexisting disease).
Lack of German language skills
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evels of cfDNA in patients with flu-like symptoms with and without SARS-CoV-2 infection and changes in concentrations during the course of illness.
- Secondary Outcome Measures
Name Time Method Correlation between cfDNA levels and laboratory and clinical parameters (e.g. hsCRP, ESR, differential blood count, temperature, oxygen saturation, respiratory rate, and accompanying symptoms)